ReviewClinical pharmacology and therapeutics2013
Network-based approaches in drug discovery and early development.
Review in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 93 citations in OpenAlex.
- Novel mechanisms of atrazine endocrine disruption: an integrated approach reveals progesterone and glucocorticoid receptor targeting.BMC pharmacology & toxicology · 2026Article
- Computational Strategies for Discovering Inhibitors Targeting Therapeutic Enzymes.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Sequence-Based Protein-Protein Interaction Prediction and Its Applications in Drug Discovery.Cells · 2025Review
- Machine Learning for Multi-Target Drug Discovery: Challenges and Opportunities in Systems Pharmacology.Pharmaceutics · 2025Review
- Role and Potential of Artificial Intelligence in Biomarker Discovery and Development of Treatment Strategies for Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2025Review
- Artificial Intelligence Models and Tools for the Assessment of Drug-Herb Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Toxicity mechanism analysis of cGAS-STING-TBK1 signaling pathway small molecule modulator based on network toxicology and molecular docking strategy: quinacrine acetate as an example.Frontiers in chemistry · 2025Article
- Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model.Current neuropharmacology · 2023Article
- Digital biomarkers and sex impacts in Alzheimer's disease management - potential utility for innovative 3P medicine approach.The EPMA journal · 2022Article
- Exploration on Molecular Mechanism of Reversal Effect of Compound Danshen Tablets on Hepatic Fibrosis Based on Network Pharmacology.Applied bionics and biomechanics · 2022Article
- Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma.The AAPS journal · 2021Article
- Diclofenac Administration after Physical Training Blunts Adaptations of Peripheral Systems and Leads to Losses in Exercise Performance: In Vivo and In Silico Analyses.Antioxidants (Basel, Switzerland) · 2021Article
- Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease.Nature communications · 2021Article
- System Genetics Including Causal Inference Identify Immune Targets for Coronary Artery Disease and the Lifespan.Circulation. Genomic and precision medicine · 2021Article
- Machine and deep learning approaches for cancer drug repurposing.Seminars in cancer biology · 2021Review
- Development of a Multi-Target Strategy for the Treatment of Vitiligo via Machine Learning and Network Analysis Methods.Frontiers in pharmacology · 2021Article
- Drug-target-ADR Network and Possible Implications of Structural Variants in Adverse Events.Molecular informatics · 2020Article
- Engineering of fluorescent or photoactive Trojan probes for detection and eradication of β-Amyloids.Drug delivery · 2020Article
- Computational/in silico methods in drug target and lead prediction.Briefings in bioinformatics · 2020Review
- Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L andJournal of medicinal chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Identification of novel targets is a critical first step in the drug discovery and development process. Most diseases such as cancer, metabolic disorders, and neurological disorders are complex, and their pathogenesis involves multiple genetic and environmental factors. Finding a viable drug target-drug combination with high potential for yielding clinical success within the efficacy-toxicity spectrum is extremely challenging. Many examples are now available in which network-based approaches show potential for the identification of novel targets and for the repositioning of established targets. The objective of this article is to highlight network approaches for identifying novel targets with greater chances of gaining approved drugs with maximal efficacy and minimal side effects. Further enhancement of these approaches may emerge from effectively integrating computational systems biology with pharmacodynamic systems analysis. Coupling genomics, proteomics, and metabolomics databases with systems pharmacology modeling may aid in the development of disease-specific networks that can be further used to build confidence in target identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.